Nuts
I guess so, but I have to admit, where Stimuvax differs from ONT-10 is a bit beyond my understanding, as they both seem to involve liposomal delivery agents.
Are they different agents in each case?
"We are excited to begin this trial of our proprietary therapeutic vaccine candidate ONT-10," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "We hope that this trial will demonstrate in cancer patients that ONT-10 can stimulate both antibodies and immune cells directed at MUC1, as it has in animal models. We are also looking forward to obtaining the first human data with the adjuvant component of ONT-10, a fully synthetic lipid A analog called PET-Lipid A, which was developed at Oncothyreon."
NutsI guess so, but I have to admit, where Stimuvax differs from...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.8¢ | 29.0¢ | $539.5K | 1.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 214062 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 469318 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |